Erschienen in:
22.03.2019 | Case Report
Immunomodulator-associated Epstein–Barr virus-positive mucocutaneous ulcer in a patient with refractory Crohn’s disease
verfasst von:
Shinsaku Hamanaka, Tomoo Nakagawa, Satoshi Ota, Mana Iida, Yuki Ohta, Yusuke Isshiki, Shingo Kasamatsu, Hideaki Ishigami, Takashi Taida, Kenichiro Okimoto, Keiko Saito, Daisuke Maruoka, Tomoaki Matsumura, Chikako Ohwada, Masahiro Takeuchi, Emiko Sakaida, Makoto Arai, Tatsuro Katsuno, Chiaki Nakaseko, Yukio Nakatani, Naoya Kato
Erschienen in:
Clinical Journal of Gastroenterology
|
Ausgabe 4/2019
Einloggen, um Zugang zu erhalten
Abstract
Epstein–Barr virus (EBV)-positive mucocutaneous ulcer is a B-cell lymphoproliferative disorder occurring in elderly or iatrogenic immunocompromised patients. We report a 27-year-old male patient with Crohn’s disease (CD) who developed immunomodulator-associated lymphoproliferative disorder. The patient was diagnosed with CD at the age of 17 and was treated with maintenance therapy including high-dose infliximab and azathioprine. When he was admitted to our hospital with a diagnosis of intestinal obstruction, his abdominal computed tomography findings showed not only colonic wall thickening and narrowing of the descending colon but also multiple liver tumor lesions. His ileus symptom improved with conservative therapy, and a pathological evaluation of the tissue biopsy specimens from the descending colon and liver lesions indicated a morphological diagnosis of EBV-positive diffuse large B-cell lymphoma. This was a case of iatrogenic immunodeficiency-associated lymphoproliferative disorder due to an immunomodulator. The treatment was initiated with chemotherapy, but he died of disease progression 10 months after the diagnosis of lymphoma. Although cases of lymphoproliferative disorder due to treatment modalities used for CD are rare in Japan, an increase in the risk of lymphoproliferative diseases should be considered in patients with CD treated with immunomodulatory agents.